Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dahvo
Cambridge, MA, USA
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Dahvo is a Cambridge-based biotechnology company focused on the discovery and development of precision oncology therapeutics. The company utilizes a synthetic lethality platform to identify novel targets and develop small molecule inhibitors for genetically defined cancers. Dahvo's lead research program targets Ubiquitin Specific Peptidase 1 (USP1), an enzyme involved in the DNA damage response pathway, with potential applications in treating BRCA-mutant and other DDR-deficient tumors. Led by a team of experienced drug hunters, Dahvo is backed by leading life science investors including ARCH Venture Partners, F-Prime Capital, and GV.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Dahvo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dahvo.